<DOC>
	<DOCNO>NCT02507843</DOCNO>
	<brief_summary>This study evaluate vitamin D adjunctive treatment patient non-Cystic Fibrosis bronchiectasis , combine vitamin D deficiency . Half participant receive vitamin D supplementation , half receive placebo .</brief_summary>
	<brief_title>Vitamin D Adjunctive Treatment Patients With Non-Cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description>To define therapeutic effect Vitamin D treatment non-Cystic Fibrosis bronchiectasis mean prospective randomize placebo-controlled double blind study follow-up least one year . To explore whether correction Vitamin D deficiency oral supplementation Vitamin D trigger vitamin D receptors-mediated cathelicidin pathway increase local systemic concentration natural antimicrobial polypeptide cathelicidin enhance eradication bacteria .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Diagnosis nonCystic fibrosis bronchiectasis High Resolution CT Age 18 year old Vitamin D deficiency [ 25 ( OH ) D &lt; 20 ng/mL ] Informed consent Current active allergic bronchopulmonary tuberculosis Diagnosis following : sarcoidosis , hyperparathyroidism , nephrolithiasis , pulmonary silicosis , Human Immunodeficiency Virus infection , liver failure , renal failure malignancy Taking benzothiadiazine derivative , cardiac glycoside , carbamazepine , phenobarbital , phenytoin primidone Taking dietary supplement topical preparation contain vitamin D 2 month first dose Treatment investigational medical product device 4 month first dose Breastfeeding , pregnant planning pregnancy Baseline correct serum calcium &gt; 2.65 mmol/L Baseline serum creatinine &gt; 125 micromol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Vitamin D</keyword>
</DOC>